A Phase 1 Study of AMG 160 in Subjects with Metastatic Castration-resistant Prostate Cancer
Skip
Study Type/Phase: Phase 1
Status: Recruiting
The purpose of this study is to evaluate the safety, effectiveness and dosing of an investigational drug called AMG 160 in patients with metastatic castration-resistant prostate cancer. AMG 160 is a type of protein being used to stimulate the body's immune system to kill cancer cells. This is a Phase 1 trial that will consist of 6 parts, but patients at El Camino Hospital will only participate in Part 5. During Part 5, AMG 160 will be administered in the El Camino Hospital outpatient infusion center. Patients will be monitored for 6 to 8 hours after the start of each AMG 160 dose in the first month. AMG 160 has not been approved for use by the U.S. Food and Drug Administration (FDA). This study includes a screening period, a treatment period lasting approximately 6 months, and a follow-up period of up to 3 years from the first dose of AMG 160.
Speak with your doctor to determine whether you meet the following criteria for participation in this study.
Inclusion Criteria | Exclusion Criteria |
---|---|
|
|
Principal Investigator
Shane Dormady, MD
Sponsor
Amgen Inc.
NCT Number
NCT03792841
Contact
Kathy Miller, Clinical Research Coordinator
Taft Center for Clinical Research
650-962-4562
kathryn_miller@elcaminohealth.org
Mandy Kaur, Clinical Research Intern
Taft Center for Clinical Research
650-691-4820
mandy_kaur@elcaminohealth.org